Hypertension Resistant to Conventional Therapy Clinical Trial
Official title:
A Prospective, Post-marketing, Single-arm, Open Label, Multi-center Clinical Study to Evaluate the Safety and Efficacy of the ReDy™ Renal Denervation System in the Treatment of Patients With Uncontrolled Hypertension
The ReDy™ System (Renal Dynamics) is a renal denervation device incorporating a variety of
ablation features and technical improvements over previously designed systems into a single
product. It is intended to treat uncontrolled (drug-resistant) hypertension by RF ablation
of the sympathetic nerve network surrounding the renal arteries.
This study will be carried out to validate the safety and the efficacy of the ReDy™ Renal
Denervation device and to demonstrate that it performs according to its intended use, i.e.
the treatment of patients with uncontrolled hypertension.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02832973 -
Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension
|
Phase 4 | |
| Terminated |
NCT02539810 -
Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)
|
Phase 4 | |
| Recruiting |
NCT02210923 -
Effect Baroreflex Activation Therapy on the Carotid Body
|
N/A | |
| Completed |
NCT02282033 -
Safety and Performance Study of the Moderato System
|
N/A | |
| Completed |
NCT01173029 -
Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
|
N/A | |
| Active, not recruiting |
NCT02837445 -
Moderato System: A Double-Blind Randomized Trial Ver 1.1
|
N/A | |
| Terminated |
NCT02653222 -
Chemical Renal Ethanol Sympatholysis Under CT Guidance Use for the Control of Therapy-Resistant Hypertension
|
Phase 2 |